VIVUS (VVUS) to Release Quarterly Earnings on Thursday

Share on StockTwits

VIVUS (NASDAQ:VVUS) will be posting its quarterly earnings results after the market closes on Thursday, November 1st. Analysts expect VIVUS to post earnings of ($1.10) per share for the quarter.

VIVUS (NASDAQ:VVUS) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.08). The company had revenue of $14.96 million during the quarter. On average, analysts expect VIVUS to post $-4 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Shares of NASDAQ:VVUS traded up $0.05 during mid-day trading on Tuesday, reaching $3.50. The stock had a trading volume of 11,271 shares, compared to its average volume of 68,249. The company has a market capitalization of $37.60 million, a P/E ratio of -1.21 and a beta of 0.58. VIVUS has a 1 year low of $3.30 and a 1 year high of $9.90.

A number of equities research analysts recently commented on the company. Zacks Investment Research upgraded VIVUS from a “sell” rating to a “hold” rating in a research report on Thursday, September 20th. ValuEngine cut VIVUS from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd.

VIVUS Company Profile

VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?

Earnings History for VIVUS (NASDAQ:VVUS)

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.

Leave a Reply